Presentation is loading. Please wait.

Presentation is loading. Please wait.

Korean Initiatives on Biotechnology: Challenges and Opportunities Expert Group Meeting, BINASIA 29-30 April, 2004 Bangkok, Thailand Sang Ki Rhee, Ph.D.

Similar presentations


Presentation on theme: "Korean Initiatives on Biotechnology: Challenges and Opportunities Expert Group Meeting, BINASIA 29-30 April, 2004 Bangkok, Thailand Sang Ki Rhee, Ph.D."— Presentation transcript:

1 Korean Initiatives on Biotechnology: Challenges and Opportunities Expert Group Meeting, BINASIA April, 2004 Bangkok, Thailand Sang Ki Rhee, Ph.D. Project Coordinator, BINASIA Korea Research Institute of Bioscience and Biotechnology

2 Biotechnology in Korea 2 Biotechnology Calendar In the 1980s : Implementing stage In the 1980s : Implementing stage 1982 Korea Biotechnology Research Association was founded Biotechnology Promotion Law was enacted KRIBB was founded. In the 1990s : Take-off stage In the 1990s : Take-off stage 1991 Bioindustry Association of Korea was founded HAN Project was launched Biotech 2000 Program (Phase I) was initiated The Year of Biotechnology was declared Biotech 2000 Program (Phase II) was launched In the 2000s : Leaping-up stage In the 2000s : Leaping-up stage 2000 Frontier Research Program was launched The Year of Biotechnology was designated 2002 Biotech 2000 Program (Phase III) was launched.

3 Biotechnology in Korea 3 National Initiatives (I) Korea recognized in early 1980s that biotechnology would emerge as a key discipline for the nations economic growth in the 21st century. Its policy makers support biotechnology with the highest priority for R&D investment in order to level up the nations competitiveness. The Korean government recently unveiled a major initiative to boost scientific R&D focusing on biotechnology. National technology road map (NTRM) for biotechnology was set up in 2002 Background Background

4 Biotechnology in Korea 4 National Initiatives (II) Implementation The governments investment on biotechnology has increased dramatically since (growth rate: 19.8% in 2003) The ratio between biotechnology and total R&D expenditure by the government has been increasing. - Biotechnology: 3.5% (94) 8% (01) 10% (03) - Average growth rate (98-01): biotechnology 46%, total R&D 19.4% The implementing policy: Selection and focus The policy has changed from unit projects in small scale for application and development to long term large scale projects for platform and research since 2000.

5 Biotechnology in Korea 5 Biotech 2000 : Overview Set up by the Korean government Objective: to place Koreas biotechnological capability at the worlds top level. Duration: (14 years) Investment: Total US$14.3 bil.(Public US$5.5bil./Private US$8.8bil.) - Phase I (94-97): US$1.5 bil.(Public US$ 482mil./Private US$ 1.0bil.) - Phase II (98-01): US$2.3 bil.(Public US$ 720mil./Private US$ 1.6bil) - Phase III (02-07): US$10.5 bil.(Public US$ 4.3bil/Private US$ 6.2bil ) Participating Agencies (7 Ministries, coordinated by MOST) - Ministry of Science and Technology (MOST) - Ministry of Commerce, Industry and Energy (MOCIE) - Ministry of Education and HRD (MOEHRD) - Ministry of Environment (MOE) - Ministry of Agriculture and Forestry (MOAF) - Ministry of Health and Welfare (MOHW) - Ministry of Marine Affairs and Fisheries (MOMAF)

6 Biotechnology in Korea 6 National Committee for Biotechnology & Bioindustry Biotech 2000 : Operating Structure (I) Industrial Applications MOAFMOHWMOEMOMAF Agro- Biotech Medical Biotech Environ. Biotech Marine Biotech MOEHRD HRD Creative Basic Research R&D Support MOST National Programs Infrastructure TRM MOCIE Industrial Platform Technol. Commercialization Industrialization Support Industrialization Support

7 Biotechnology in Korea 7 Biotech 2000 : Operating Structure (II) National Committee for Biotechnology & Bioindustry Korea Biotechnology Research Association Bioindustry Association of Korea Korea Bioventure Association Private Companies Korea Biotechnology Research Association Bioindustry Association of Korea Korea Bioventure Association Private Companies Korea Research Institute of Bioscience and Biotechnology Other governmental or public research institutions Korea Research Institute of Bioscience and Biotechnology Other governmental or public research institutions Universities Research Centers (SRC, ERC, RRC, MRC) National Research Laboratories Universities Research Centers (SRC, ERC, RRC, MRC) National Research Laboratories MOST, MOCIE, MOEHRD, MOHW, MOE, MOAF, MOMAF IndustryIndustry AcademiaAcademia Research Institutions

8 Biotechnology in Korea 8 Biotech 2000 : Strategic Objectives To increase the commercializing capability and expand the nations world market share of domestic bioproducts to 5 % To develop platform technology and improve industrial R&D capability To establish a scientific foundation for the development of novel biotechnology III(2002~2007) II(1998~2001) I(1994~1997) ObjectivePhase

9 Biotechnology in Korea 9 The government spent U$ 482 million for R&D during the Phase I, and U$ 720 million during the Phase II. Biotech 2000 : Investment (Unit : U$ mil.) Agency Phase I (94-97) Phase II (98-01) Total Phase III ( ) Sub Total MOST ,8922,478 MOEHRD MOAF MOCIE MOHW MOE MOMAF Total ,1334,3035,505 In the Phase III, the total investment is expected to increase substantially to U$ 4,303 million.

10 Biotechnology in Korea 10 Ministry of Science and Technology (I) Role Supports for R&D activities from basic science to application Major Programs G-7 Project (HAN Project) 21C Frontier Science Program G-7 Project (HAN Project) 21C Frontier Science Program G-7 Project Duration: , Total Budget: U$ 193 million Main Area: Screening of lead compounds and commercialization G-7 Project Duration: , Total Budget: U$ 193 million Main Area: Screening of lead compounds and commercialization 21C Frontier Science Program Supports core science and emerging technologies for 21 st century Duration: , Total Budget: U$ 3.6 billion Main Areas: - Functional analysis of human, microbial and crop genomes - Biodiversity of indigenous plants - Stem cell biology and therapeutic applications - Proteomics research - High throughput screening of novel compounds for bioregulators using structural biology and pharmacogenomics 21C Frontier Science Program Supports core science and emerging technologies for 21 st century Duration: , Total Budget: U$ 3.6 billion Main Areas: - Functional analysis of human, microbial and crop genomes - Biodiversity of indigenous plants - Stem cell biology and therapeutic applications - Proteomics research - High throughput screening of novel compounds for bioregulators using structural biology and pharmacogenomics

11 Biotechnology in Korea 11 Ministry of Science and Technology (II) Role Supports for R&D activities ranging basic science to application Major Programs National R&D Program Basic Life Science Promotion Program National R&D Program Basic Life Science Promotion Program National R&D Programs Duration: , Total Budget: U$ 600 million Main Areas: - BioDiscovery Program (Screening and development of new drugs ) - BioChallenge Program (Preclinical studies and commercialization of biodrugs) - BioFusion Program (Integrated technology with IT and NT) - BioInfra Program (National Genome Information Center) National R&D Programs Duration: , Total Budget: U$ 600 million Main Areas: - BioDiscovery Program (Screening and development of new drugs ) - BioChallenge Program (Preclinical studies and commercialization of biodrugs) - BioFusion Program (Integrated technology with IT and NT) - BioInfra Program (National Genome Information Center) Basic Life Science Promotion Program Supports for basic life science programs Duration: Main Area: SRC, ERC, RRC, MRC Basic Life Science Promotion Program Supports for basic life science programs Duration: Main Area: SRC, ERC, RRC, MRC

12 Biotechnology in Korea 12 Ministry of Commerce, Industry and Energy Ministry of Commerce, Industry and Energy Role Builds infrastructure for industrialization and commercialization Major Programs Industrial Platform Technology Development Develops common platform technology, mid-term core technology and technology for next generation Duration: 1992~, Total Budget: U$ 808 million Main Areas: - Development of processes for bioenergy production - Development of biosensors, BIOMEMS, Biomimics - Development of DNA microarrays and protein chips (Lab-on-a-chip) - Cell culture technology for therapeutic proteins - Infrastructure (GMP, Bioclusters) Industrial Platform Technology Development Develops common platform technology, mid-term core technology and technology for next generation Duration: 1992~, Total Budget: U$ 808 million Main Areas: - Development of processes for bioenergy production - Development of biosensors, BIOMEMS, Biomimics - Development of DNA microarrays and protein chips (Lab-on-a-chip) - Cell culture technology for therapeutic proteins - Infrastructure (GMP, Bioclusters)

13 Biotechnology in Korea 13 Ministry of Education and Human Resources Development Role Supports for the development of HR in biotechnology Major Programs Brain Korea 21 Program Duration: , Total Budget: U$ 150 million Major Areas: - Human resources development in higher learning and industrial skills - Reform of higher education programs - Upgrade of graduate research infrastructure in biotechnology Brain Korea 21 Program Duration: , Total Budget: U$ 150 million Major Areas: - Human resources development in higher learning and industrial skills - Reform of higher education programs - Upgrade of graduate research infrastructure in biotechnology

14 Biotechnology in Korea 14 Ministry of Health and Welfare Role Supports for the development of biotechnology in public health and medical sectors Major Programs Medical Biotechnology and Biopharmaceuticals Duration: , Total Budget: U$ 900 million Major Areas: - Prevention, diagnosis, and treatments of diseases to improve public health - Development of new drugs - Development of vaccines, anti-aging and anti-cancer new drugs - Analysis of Korean genome types - Neurobiology and brain research (Braintech 21) - Gene therapy Medical Biotechnology and Biopharmaceuticals Duration: , Total Budget: U$ 900 million Major Areas: - Prevention, diagnosis, and treatments of diseases to improve public health - Development of new drugs - Development of vaccines, anti-aging and anti-cancer new drugs - Analysis of Korean genome types - Neurobiology and brain research (Braintech 21) - Gene therapy

15 Biotechnology in Korea 15 Ministry of Agriculture and Forestry Role Supports for R&D in agrobiotechnology and horticulture Major Programs BioGreen 21 Program Duration: , Total Budget: U$ 1 billion Major Areas: - Collection, assessment, preservation of genetic resources of biodiversity - Development of breeding technology for transgenic animals and plants - Research on animal and plant genomics - Biosafety issues on GMOs - Biodiversity and Bioprospecting BioGreen 21 Program Duration: , Total Budget: U$ 1 billion Major Areas: - Collection, assessment, preservation of genetic resources of biodiversity - Development of breeding technology for transgenic animals and plants - Research on animal and plant genomics - Biosafety issues on GMOs - Biodiversity and Bioprospecting

16 Biotechnology in Korea 16 Ministry of Environment Role Supports for R&D in environmental biotechnology Major Programs Environmental Biotechnology Promotion Program Duration: , Total Budget: U$ 116 million Major Areas: - Screening and isolation of environmental microbes - Bioremediation - Development of biosensors for monitoring of environmental pollutants - Conservation of natural environment and sustainable development Environmental Biotechnology Promotion Program Duration: , Total Budget: U$ 116 million Major Areas: - Screening and isolation of environmental microbes - Bioremediation - Development of biosensors for monitoring of environmental pollutants - Conservation of natural environment and sustainable development

17 Biotechnology in Korea 17 Ministry of Marine Affairs and Fisheries Ministry of Marine Affairs and Fisheries Role Supports for R&D in marine biotechnology and aquaculture Major Programs Marine Biotechnology and Aquaculture Technology Promotion Programs Duration: , Total Budget: U$ 100 million Major Areas: - Bioprospecting from marine bioresources - Search and utilization of polar biodiversity - Development of transgenic fishes - Development of new aquaculture technology - Screening of marine GMOs Marine Biotechnology and Aquaculture Technology Promotion Programs Duration: , Total Budget: U$ 100 million Major Areas: - Bioprospecting from marine bioresources - Search and utilization of polar biodiversity - Development of transgenic fishes - Development of new aquaculture technology - Screening of marine GMOs

18 Biotechnology in Korea 18 Bioindustry Domestic biotechnology market Types of business Description Total ,000 Type Pharma- ceuticals FoodChemicalsAgriculture Process Engineering Environment % DescriptionKoreaUSAJapanEU Market Size (U$ mil.) 90022,3007,2006,000 Growth Rate (%) Korea vs. World (as of 2000) (Unit: US mil.)

19 Biotechnology in Korea 19 Investment in Bioindustry Total R&D spending in bioindustry (Unit : U$ mil.) Investment plans Description Total CJ: U$ 1.4 bil. for R&D for 5 years ( ) - Samsung Fine Chemicals: U$ 300 mil. for R&D for 3 years ( ) - LGCI: U$ 50 mil. invested to bioventures in SK Global: U$ 35 mil. invested to bioventures in Hanwha Chemical Co.: U$ 50 mil. for R&D in Hansol: U$ 150 mil. for R&D from 2000 to Isu Chemical : U$ 150 mil. for R&D in the period of

20 Biotechnology in Korea 20 Bioventures Governments initiative to boost bioventure business Governments initiative to boost bioventure business Current status and prospects of bioventures in Korea Current status and prospects of bioventures in Korea Description No. of start-ups ,000 No. of employees6,50015,00045,000 Market Size (U$ bil.) MOCIE pushes a 5-year program to encourage the bioventure business. It earmarked a U$ 30 mil. fund in FY 2000's budget to develop the infrastructure needed by bioventure start-ups. - Focusing on commercialization of biotechnology, the Korean government announced a package that envisages to create 600 bioventures by 2003 and to expand the number to 1,000 by 2007.

21 Biotechnology in Korea 21 Amino acids : 20 % share of world market in 2000 (U$ 75 million) Facts and Status : the Success Story Ryfamycin : 10% share of world market in 2000 (U$ 7.5 million) Hepatitis B Vaccine : Developed in 1987 by Korea Green Cross Corp. World market share was rapidly increased (40% in 1999) Recombinant human growth hormone : Developed by LG Chemical Ltd. Technology transferred to SmithKline Beecham of U.K. in First domestic new drug, Sunpla, for anticancer: Developed in 1997 by SK Chemicals and approved by KFDA. Technology transferred to Johnson & Johnson Co. First global new drug, Factive, for anti-infectious diseases : Developed by LGCI and approved by FDA in About 300 new drugs are under development. Among them, 23 new drugs are in progress or in completion of clinical trials for FDA approval.

22 Biotechnology in Korea 22 Manpower in Biotechnology By degrees Description Total Number7,5958,2308,4859,392 Ph. D. (%) M. S. (%) B. S. (%) Description Total Number7,5958,2308,4859,392 Universities (%) Private Companies (%) Government Research Institutions (%) By distribution

23 Biotechnology in Korea 23 Patents & Publications Publications in SCI journals ( in genomics and proteomics) Publications in SCI journals ( in genomics and proteomics) Description Korea USA2,8714,0044,3184,500 Japan6431,1471,2381,236 Korea/USA (%) Korea/Japan (%) US patents registered US patents registered Description Korea2083 USA2,99310,480 Japan7411,153 Korea/USA (%) Korea/Japan (%)2.77.2

24 Biotechnology in Korea 24 Background Biosafety Issues Governmental agencies in charge Governmental agencies in charge AgencyRole / Activities MOFAT Focal point MOST Preparation of regulatory guidelines to oversee recombinant DNA plants MOHW Providing guidelines for recombinant DNA experimental research MOE Proposed to the National Assembly to enact a law regulating research with an environmental impact and industrial applications MOCIE Preparing a draft law to supervise the National Assembly with biosafety management and the import and export of LMOs for enactment - In 2000, more than 130 countries including Korea reached an agreement to adopt the Biosafety Protocol which applies to the transboundary movement, transit, handling and use of all LMOs. - The Korean government set up an interministrial committee to assess the safety of LMO products in The Act for trans-boundary movement of LMOs was enacted in 2001.

25 Biotechnology in Korea 25 International Cooperation Description All AreasBiotech. Areas No. of Projects Spending (A) (U$ mil.) No. of Projects Spending(B) (U$ mil.) Percentage (B/A) MOST KOSEF MOCIE RDA International joint research projects in 2000 International joint research projects in 2000 * RDA: Rural Development Administration Overseas Cooperation Programs & joint research centers Overseas Cooperation Programs & joint research centers - Joint Research Center at the Fred Hutchinson Cancer Research Center, USA - Korea-UK Bioindustry Collaboration Program (HGMPRC, Bio-Nano IRC) - Korea-France S&T Focal Points Program (focal point in biotech area) - Korea-China Bioscience and Biotechnology Cooperation Center (Shanghai Institutes for Biological Sciences, CAS) - Korea-Israel Biotechnology Collaboration Program (Weizmann Ins. of Science) - Bioventure Incubating Centers (Germany, USA)

26 Biotechnology in Korea 26 Strengths Challenges and Opportunities : SWOT Analysis (I) Challenges and Opportunities : SWOT Analysis (I) Weaknesses - Strong drive policy by the government - Good R&D infrastructure in industry, universities and research institutes - Booming bioventure business - Skilled manpower - Strong knowledge and industry bases - Shortage of innovative R&Ds for platform technology - Comparatively insufficient R&D expenditure - Weak link between industry and academia - Small domestic market and limited marketing power for global sales - Poor biodiversity and bioresources

27 Biotechnology in Korea 27 Opportunities Challenges and Opportunities : SWOT Analysis (II) Challenges and Opportunities : SWOT Analysis (II) Threats - Paradigm shift in biotechnology for post genomic era - Top priority in national R&D projects - Increase of public awareness in health and welfare - Emerging new technology innovation - Growing competition worldwide - Depression of local investment atmosphere - Regulatory issues: biosafety and bioethics

28 Biotechnology in Korea 28 Competitiveness DescriptionTechnology Competitiveness (% of Top Level) Basic Technology Genetic Engineering/Genomics Protein Engineering/Proteomics Cell Engineering/Immunology Transgenic Animals/Plants 80/50 70/50 80/60 85/70 New Drug Development Screening Structure Analysis Efficacy/Valuation Biosafety Evaluation Process Development Fermentation/Process Cell Culture Technology Bioreactor Design Separation/Purification 90/ Overall (%)60-70 (as of 2002)

29 Biotechnology in Korea 29 Vision 2010 – – 13th in the world 2000 Competitiveness – – –7–7 –7–7 – – 2010 G-7 level 5% of total governmental R&D spending R&D Spending R&D Capability (% of top level) - Basic: 70% - NDD: 50% - Process: 70% Market Size: - World: U$ 54 bil. - Korea: U$ 0.9 bil. Share: 1.7 % of world market 20% of total governmental R&D spending - Basic: 90% - NDD: 90% - Process: 90% Size: - World: U$150 bil. - Korea: U$ 10 bil. Share: 6.6% of world market

30 Biotechnology in Korea 30 Summary Biotechnology is a key platform to accelerate the national economic growth in Korea. Korea has set up a solid strategy to achieve international competitiveness by leveraging existing capabilities and creating new strengths. - selection and focus on the areas with high international competitiveness - implementation of inter-ministerial coordination for biotechnology development - promotion of international cooperation and strategic alliances

31 Biotechnology in Korea 31 Thank you !

32 Biotechnology in Korea 32 What should be put in BINASIA? Science and Technology Related Data National Science and Technology Policies National Policies on Biotechnology Biotechnology R&D Activities Status of Biological Diversity Biosafety Protocol Manpower Training Centers / Programs International Cooperation in Biotech Area Bilateral Cooperation with Member Countries and beyond Biotechnology Infrastructure National Budget for the Promotion of Biotechnology

33 Biotechnology in Korea 33 Key Factors - Part A: Basic Data – Land Area, Population, GNP - Part B: R&D – National R&D Expenditures in Total, National R&D Expenditures in Biotech - Part C: Human Resources – Number of Scientists in Biotech Area in Total, Number of Scientists in Biotech Area by Sector - Part D: Biotechnology Development and Diffusion – Bioindustry Market (in Total and by Sector), International Trade in Bioproducts, Number of Biotechnology Companies (Venture, Established), Number of Patents(in Total, by Field), Number of Publications (Domestic and Overseas), etc. - Part E: International Cooperation – Number of Bilateral & Multinational Agreements (MOU), Number of International Cooperation Centers, Number of International Joint Research Projects


Download ppt "Korean Initiatives on Biotechnology: Challenges and Opportunities Expert Group Meeting, BINASIA 29-30 April, 2004 Bangkok, Thailand Sang Ki Rhee, Ph.D."

Similar presentations


Ads by Google